Filed by newsfilecorp.com Orgenesis Inc. Enters Into Agreement to Commence Advanced Studies for Proposed Diabetes Treatment WHITE PLAINS, NY (MARKETWIRE

Orgenesis Inc. Enters Into Agreement to Commence Advanced

Studies for Proposed Diabetes Treatment

WHITE PLAINS, NY (MARKETWIRE April 11, 2012) Orgenesis

( Orgenesis or the Company ), a development stage company

with a novel therapeutic technology dedicated to convert a patient s own liver

cells into functional insulin-producing cells as a treatment for diabetes, is

pleased to announce entry into an agreement to commence a comprehensive research

study into the efficacy of its treatment in order to more efficiently move the

technology towards future human clinical trials.

Effective March 22, 2012, Orgenesis Inc. has entered into an

agreement with Tel Hashomer - Medical Research, Infrastructure and Services Ltd.

("THM"). In exchange for certain fees, licensing rights and other

considerations, THM is to perform a study at the facilities and using the

equipment and personnel of the Chaim Sheba Medical Center of Israel under the

direct supervision of Orgenesis Chief Science Officer, Prof. Sarah Ferber.

THM will conduct the study, through the services of the Medical

Research Infrastructure Development and Health Services Fund established by the

Sheba Medical Center pursuant to the Research Program under the direct

supervision of Prof. Ferber, who will conduct and supervise the study with the

assistance of the employees, researchers and/or associates of the Hospital

and/or the Fund. The study itself shall be performed pursuant to the laws,

regulations and guidelines as applicable in Israel with respect to clinical

research on human subjects.

Company CEO Jacob BenArie comments, We are very pleased to

commence this advanced stage of our development. Over the course of the upcoming

year, we aim to prove our technology s effectiveness in the treatment of

diabetes and this study is a major step towards the development of our methods

and in refining our plans for the eventual introduction to the world at large.

Our partnership with Tel Hashomer and through them our ability to work with the

team at Chaim Sheba Medical Centre provides us with world class facilities and

talent in which to ensure we achieve the best possible results within definable

timelines. We look forward to further announcements as interim results become

Orgenesis invites interested readers to visit our website at

www.orgenesis.com to find out more about the Company and its goal to

bring about the end of diabetes as we now know it.

Further details of the Company s business, finances,

appointments and agreements can be found as part of the Company s continuous

public disclosure as a reporting issuer under the Securities Exchange Act of

1934 filed with the Securities and Exchange Commission s ( SEC ) EDGAR database.

For more information visit: www.orgenesis.com.

About Orgenesis Inc. (OTCBB: ORGS)

development stage company with a novel therapeutic technology that employs a

molecular and cellular approach directed at converting a patient s own liver

cells into functional insulin producing cells, as a treatment for diabetes. The

Company believes that converting the diabetic patient s own tissue into

insulin-producing cells overcomes the problem of donor shortage and removes the

risk of transplant rejection. If successful, this could mean the end of diabetes

as we now know it. For more information visit: www.orgenesis.com.

Notice Regarding Forward-Looking

Statements in this press release that are not strictly

historical in nature are forward-looking statements. These statements are only

predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements

in this press release include that this study will help prove our technology s

effectiveness in the treatment of diabetes within definable timelines.. Actual

events or results may differ materially from those projected in any of such

statements due to various factors, including the risks and uncertainties

inherent in drug discovery and development, which include, without limitation,

the potential failure of development candidates to advance through preclinical

studies or demonstrate safety and efficacy in clinical testing and the ability

to pass clinical trials so as to move on to the next phase, our ability to

retain key employees and our ability to finance development or satisfy the

rigorous regulatory requirements for new drugs. Competitors may develop better

or cheaper alternatives to our products. Readers are cautioned not to place

undue reliance on these forward-looking statements, which speak only as of the

date hereof. All forward-looking statements are qualified in their entirety by

this cautionary statement and we undertake no obligation to revise or update

this press release to reflect events or circumstances after the date hereof..

Investors should refer to the risk factors disclosure outlined in our periodic

reports filed from time-to-time with the Securities and Exchange Commission.

On Behalf of the Board

Vered Caplan, Chairperson